ARA-290 10mg Research Peptide
ARA-290 is a synthetic 11-amino-acid peptide derived from the helix-B domain of erythropoietin. Developed by Araim Pharmaceuticals (now Cibinetide), it activates the innate repair receptor (IRR) — a heteroreceptor of EPOR and CD131 — without binding the classical EPO receptor responsible for red-cell production.
Purity
99.2% HPLC-tested purity with COA support.
Size
10mg Lyophilized Powder.
Storage
-20°C (Freezer)
Research use
For laboratory research use only. Not for human or veterinary use.
Mechanism of action
ARA-290 selectively activates the tissue-protective innate repair receptor (IRR), triggering anti-inflammatory, anti-apoptotic and neuroprotective signaling without raising hemoglobin or hematocrit. Clinical trials in sarcoidosis-associated small-fiber neuropathy and diabetic neuropathy have shown reductions in pain scores and improvements in nerve fiber density.
Research applications
- Neuropathic pain research
- Small-fiber neuropathy studies
- Diabetic neuropathy research
- Sarcoidosis-associated neuropathy studies
- Tissue protection and ischemia research
Frequently asked questions
Why is ARA-290 used instead of EPO?
ARA-290 separates the tissue-protective effects of EPO (via the IRR) from its erythropoietic effects (via the EPOR homodimer). Researchers get the neuroprotection without raising hematocrit.
What's the strongest published evidence for ARA-290?
Phase II trials in sarcoidosis-associated small-fiber neuropathy showed significant reduction in neuropathic pain scores and improvements in intra-epidermal nerve fiber density.
Do you provide a COA?
Yes. ≥99.2% HPLC purity, mass-spec confirmation, endotoxin testing — included on every batch.
Browse research peptides for sale · View lab reports · Read peptide FAQ